US Government Patent 6630507

Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email
User Review
0 (0 votes)

Does the US Govt. Really have a PATENT on CBD?

Well the answer to that yes, obviously. Why else would they try to OUTLAW it?

*Puts on Tinfoil Hat – Below is an excerpt found from the USPTO website; detailing the patent in question. 

United States Patent6,630,507
Hampson ,   et al.October 7, 2003
**Please see images for: ( Certificate of Correction ) **

Cannabinoids as antioxidants and neuroprotectants 


Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH.sub.3, and COCH.sub.3. ##STR1##

Inventors:Hampson; Aidan J. (Irvine, CA), Axelrod; Julius (Rockville, MD), Grimaldi; Maurizio (Bethesda, MD)
Assignee:The United States of America as represented by the Department of Health and Human Services (Washington, DC) 
Family ID:26767641
Appl. No.:09/674,028
Filed:February 2, 2001
PCT Filed:April 21, 1999
PCT No.:PCT/US99/08769
PCT Pub. No.:WO99/53917
PCT Pub. Date:October 28, 1999

Current U.S. Class:514/454
Current CPC Class:A61K 31/35 (20130101)
Current International Class:A61K 31/35 (20060101); A61K 031/35 ()
Field of Search:;514/454

References Cited [Referenced By]

U.S. Patent Documents

2304669December 1942Adams
4876276October 1989Mechoulam et al.
5227537July 1993Stoss et al.
5284867February 1994Kloog et al.
5434295July 1995Mechoulam et al.
5462946October 1995Mitchell et al.
5512270April 1996Ghio et al.
5521215May 1996Mechoulam et al.
5538993July 1996Mechoulam et al.
5635530June 1997Mechoulam et al.
5696109December 1997Malfroy-Camine et al.
6410588June 2002Feldmann et al.

Foreign Patent Documents

 427518 May 1991 EP
 576357 Dec 1993 EP
 656354 Jun 1995 EP
 658546 Jun 1995 EP
 WO9305031 Mar 1993 WO
 WO9412667 Jun 1994 WO
 WO9612485 May 1996 WO
 WO9618600 Jun 1996 WO
 WO9719063 May 1997 WO
 99/53917 Oct 1999 WO

Other References

Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.* .
Mechoulam et al., “A Total Synthesis of d1-.DELTA..sup.1 -Tetrahydrocannabinol, the Active Constituent of Hashish.sup.1,” Journal of the American Chemical Society, 87:14:3273-3275 (1965). .
Mechoulam et al., “Chemical Basis of Hashish Activity,” Science, 18:611-612 (1970). .
Ottersen et al., “The Crystal and Molecular Structure of Cannabidiol,” Acta Chem. Scand. B 31, 9:807-812 (1977). .
Cunha et al., “Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients.sup.1,” Pharmacology, 21:175-185 (1980). .
Consroe et al., “Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats,” Experimental Neurology, Academic Press Inc., 70:626-637 (1980). .
Turkanis et al., “Electrophysiologic Properties of the Cannabinoids,” J. Clin. Pharmacol., 21:449S-463S (1981). .
Carlini et al., “Hypnotic and Antielpileptic Effects of Cannabidiol,” J. Clin. Pharmacol., 21:417S-427S (1981). .
Karler et al., “The Cannabinoids as Potential Antiepileptics,” J. Clin. Pharmacol., 21:437S-448S (1981). .
Consroe et al., “Antiepileptic Potential of Cannabidiol Analgos,” J. Clin. Pharmacol., 21:428S-436S (1981). .
Colasanti et al., “Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol,” Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984). .
Colasanti et al., “Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol,” Exp. Eye Res., Academic Press Inc., 39:251-259 (1984). .
Volfe et al., “Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients,” Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985). .
Agurell et al., “Pharmacokinetics and Metabolism of .DELTA..sup.1 -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*,” Pharmacological Reviews, 38(1):21-43 (1986). .
Karler et al., “Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,”NIDA Res. Monogr., 79:96-107 (1987). .
Samara et al., “Pharmacokinetics of Cannabidiol in Dogs,” Drug Metabolism and Disposition, 16(3):469-472 (1988). .
Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,” Neuron, Cell Press, 1:623-634 (1988). .
Eshhar et al., “Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist,” European Journal of Pharmacology, 283:19-29 (1995). .
Skaper et al., “The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons,” Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996). .
Alonso et al., “Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules,” J. Org. Chem., American Chemical Society, 62(2):417-421 (1997). .
Combes et al. “A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation,” Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997). .
Shohami et al., “Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome,” Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997). .
Zurier et al., “Dimethylheptyl-THC-11 OIC Acid,” Arthritis & Rheumatism, 41(1):163-170 (1998). .
Hampson et al., “Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission,” Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998). .
Hampson et al., “Cannabidiol and (-).DELTA..sup.9 -tetrahydrocannabiono are Neuroprotective Antioxidants,” Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998)..</align=”left”>

Primary Examiner: Weddington; Kevin E. 
Attorney, Agent or Firm: Klarquist Sparkman, LLP 

Parent Case Text

This application is a 371 of PCT/US99/08769 filed Apr. 21, 1999, which claims benefit of No. 60/082,589 filed Apr. 21, 1998, which claims benefit of No. 60/095,993 filed Aug. 10, 1998.


We claim: 

1. A method of treating diseases caused by oxidative stress, comprising administering a therapeutically effective amount of a cannabinoid that has substantially no binding to the NMDA receptor to a subject who has a disease caused by oxidative stress. 

2. The method of claim 1, wherein the cannabinoid is nonpsychoactive. 

3. The method of claim 2, wherein the cannabinoid has a volume of distribution of 10 L/kg or more. 

4. The method of claim 1, wherein the cannabinoid is not an antag

User Review
0 (0 votes)
Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email

Leave a Comment

Your email address will not be published. Required fields are marked *